The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

摘要: Real-time quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) is increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral blood BCR-ABL/ABL ratio, as assessed by Q-RT-PCR, has been shown correlate with the contemporary cytogenetic response patients receiving imatinib (Glivec, Gleevec). We have Q-RT-PCR early molecular 4 weeks and 3 months of therapy, 47 established CML. After whose ratio had fallen less than 50% that baseline a significantly higher probability achieving major after 6 when compared those did not fall this amount (P < 0.001). Similarly, at was 10% remission Patients who achieved these falls their either or superior progression-free survival median follow-up 16.5 = 0.01 0.003 respectively). These effects were independent patient age disease stage. occurrence cytopenias sufficiently severe interrupt therapy unrelated survival. In conclusion, data suggest trend may be clinically useful for identification destined fare poorly on imatinib.